Electroconvulsive Therapy, Transcranial Magnetic Stimulation, and Deep Brain Stimulation in Treatment-Resistant Depression

Abstract

Treatment-resistant depression (TRD) continues to challenge current therapeutic options, especially pharmacologic treatments often used as first-line management. Thus, multimodality treatments, including neurostimulation techniques, are sought for symptom improvement. Since the first use of electroconvulsive therapy (ECT), the field of neurostimulation has strived to find treatments that improve safety, efficacy, and the side-effect profile to provide relief for patients suffering from TRD. Development in neurostimulation is spurred by ongoing innovation in technology, but also by increasing awareness that TRD frequently requires multimodal approaches for optimal symptom relief. This article reviews the most recent advances in ECT, transcranial magnetic stimulation (TMS), and deep brain stimulation (DBS) for use in TRD. ECT, TMS, and DBS are all researched in the treatment of depression, with ECT and TMS having approval from the US Food and Drug Administration, but differ widely in techniques, protocols, and patient selection parameters. ECT has the most data backing efficacy, but needs ancillary support (anesthesia, support staff) for implementation, and considerable stigma still represents an obstacle to widespread use. TMS and DBS, although less efficacious than ECT, are gaining popularity and as additional knowledge is acquired in regards to ideal use, circumstances may allow for them to become mainstream treatments for TRD in the next decade. [ Psychiatr Ann . 2016;46(4):240–246.]